Drug Trial Radar · NCT05546879
Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable HCC
Last checked: Nov 19, 2026Latest source record: May 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
43
Actual
Start
Mar 15, 2023
Primary completion
Mar 19, 2026
Study completion Mar 19, 2029
Sponsor
- Lead sponsor
- University Hospital, GrenobleAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- NETRIS Pharma
- First posted
- Sep 21, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will assess the safety of the association of NP137 with the standard of care Atezolizumab-Bevacizumab in first line setting in patients with unresectable hepatocellular carcinoma. The study drug which is tested is the NP137 in association with Atezolizumab-Bevacizumab to allow a better tumor response as well as better survival outcomes with an acceptable safety.
Conditions
- Hepatocellular Carcinoma
Interventions
NP137Drug
NP137 at 9 or 14 mg/kg IV will be administered every 21 days.
AtezolizumabDrug
Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-days cycle
BevacizumabDrug
Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage Proportion of patients experiencing adverse eventsTime frame: At 36 months
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
CHU Angers
Angers, France
Hôpital Haut Lêveque
Bordeaux, France
12 Hôpital St Joseph
Marseille, France
CHU Nantes
Nantes, France
AP-HP Beaujon
Paris, France
AP-HP St Antoine
Paris, France
CHU Reims
Reims, France
CHU Toulouse
Toulouse, France
CHU de GRENOBLE ALPES
Grenoble, Alpes, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.